Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 7/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3737669 | 0.81 | CYP17A1 (0.39) | PDCD1CD274MAPTAURKBTP53 | |
| SCHEMBL7244128 | 0.81 | SMN1; SMN2 (0.40) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL2144487 | 0.78 | ALDH1A1 (0.46) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| Cyclopropane SCHEMBL2444392 | 0.74 | STK17B (0.44) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| Cyclopropane SCHEMBL2438672 | 0.74 | TP53 (0.49) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL17442612 | 0.74 | AURKB (0.40) | MAPTAURKBNPC1RAB9A | |
| SCHEMBL7214959 | 0.73 | BRD4 (0.38) | MAPT | |
| SCHEMBL7089986 | 0.73 | SMN1; SMN2 (0.63) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL7247038 | 0.73 | HIF1A (0.47) | NPC1RAB9A | |
| SCHEMBL17442864 | 0.72 | ROCK1 (0.42) | AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | PDCD1 3666/4885CD274 4361/4885MAPT 2802/4885 |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | PDCD1 3666/4885CD274 4361/4885MAPT 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.